Effects of vehicles on the percutaneous absorption of donepezil hydrochloride across the excised hairless mouse skin

References

• Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. (1995). Synthesis and structure-activity relationships of acetylcholinestrase inhibitors: 1-benzil-4-[(5,6-dimethoxy-1-oxoindan-2yl)methyl]piperidine hydrochloride and related compounds. J Med Chem, 38:4821–4829.
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology, 50:136–145.
   PubMed Web of Science ®Google Scholar
• Collerton D. (1986). Cholinergic function and intellectual decline in Alzheimer’s disease. Neuroscience, 19:1–28.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. (1982). Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science, 215:1237–1239.
   PubMed Web of Science ®Google Scholar
• Machado JC, Caramelli P. (2006). Treatment of dementia: anything new? Curr Opin Psychiatry, 19:575–580.
   PubMed Web of Science ®Google Scholar
• Winblad B, Jelic V. (2004). Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord, 18 Suppl 1:S2–S8.
   PubMed Web of Science ®Google Scholar
• Bassil N, Grossberg GT. (2009). Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease. CNS Drugs, 23:293–307.
   PubMed Web of Science ®Google Scholar
• Small G, Dubois B. (2007). A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr Med Res Opin, 23:2705–2713.
   PubMed Web of Science ®Google Scholar
• Cummings J, Winblad B. (2007). A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia. Expert Rev Neurother, 7:1457–1463.
   PubMedGoogle Scholar
• El Maghraby GM, Alanazi FK, Alsarra IA. (2009). Transdermal delivery of tadalafil. I. Effect of vehicles on skin permeation. Drug Dev Ind Pharm, 35:329–336.
   PubMed Web of Science ®Google Scholar
• Rastogi R, Anand S, Dinda AK, Koul V. (2010). Investigation on the synergistic effect of a combination of chemical enhancers and modulated iontophoresis for transdermal delivery of insulin. Drug Dev Ind Pharm, 36:993–1004.
   PubMed Web of Science ®Google Scholar
• Thakur RA, Michniak BB, Meidan VM. (2007). Transdermal and buccal delivery of methylxanthines through human tissue in vitro. Drug Dev Ind Pharm, 33:513–521.
   PubMed Web of Science ®Google Scholar
• Kafkala S, Matthaiou S, Alexaki P, Abatzis M, Bartzeliotis A, Katsiabani M. (2008). New gradient high-performance liquid chromatography method for determination of donepezil hydrochloride assay and impurities content in oral pharmaceutical formulation. J Chromatogr A, 1189:392–397.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Furuya R, Takahata T, Tateishi T. (2002). Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci, 768:261–265.
   PubMed Web of Science ®Google Scholar
• Barry BW. (1983). Dermatological Formulations. New York, USA: Marcel Dekker.
   Google Scholar
• Aungst BJ, Blake JA, Hussain MA. (1990). Contributions of drug solubilization, partitioning, barrier distruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharm Res, 7:712–718.
   PubMed Web of Science ®Google Scholar
• Kasting GB, Smith RL, Anderson BD. (1992). Prodrugs for dermal delivery: solubility, molecular size, and functional group effects. In: Sloan KB ed. Prodrugs. New York, USA: Marcel Dekker, pp. 117–161.
   Google Scholar
• Potts RO, Guy RH. (1992). Predicting skin permeability. Pharm Res, 9:663–669.
   PubMed Web of Science ®Google Scholar
• Green PG, Guy RH, Hadgraft J. (1988). In vitro and in vivo enhancement of skin permeation with oleic acid and lauric acids. Int J Pharm, 48:103–111.
   Google Scholar
• Yamada M, Uda Y, Tanigawara Y. (1987). Mechanism of enhancement of percutaneous absorption of molsidomine by oleic acid. Chem Pharm Bull, 35:3399–3406.
   PubMed Web of Science ®Google Scholar
• Nomura H, Kaiho F, Sugimoto Y, Miyashita Y, Dohi M, Kato Y. (1990). Percutaneous absorption of indomethacin from mixtures of fatty alcohol and propylene glycol (FAPG bases) through rat skin: effects of oleic acid added to FAPG base. Chem Pharm Bull, 38:1421–1424.
   PubMed Web of Science ®Google Scholar
• Kim J, Cho Y, Choi H. (2000). Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin. Int J Pharm, 196:105–113.
   PubMed Web of Science ®Google Scholar
• Cho YJ, Choi HK. (1998). Enhancement of percutaneous absorption of ketoprofen: effect of vehicles and adhesive matrix. Int J Pharm, 86:95–104.
   Google Scholar
• Gwak HS, Kim SU, Chun IK. (2002). Effect of vehicles and enhancers on the in vitro permeation of melatonin through hairless mouse skin. Arch Pharm Res, 25:392–396.
   PubMed Web of Science ®Google Scholar
• Gwak HS, Oh IS, Chun IK. (2004). Transdermal delivery of ondansetron hydrochloride: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm, 30:187–194.
   PubMed Web of Science ®Google Scholar
• Choi JS, Cho YA, Chun IK, Jung SY, Gwak HS. (2007). Formulation and evaluation of ketorolac transdermal systems. Drug Deliv, 14:69–74.
   PubMed Web of Science ®Google Scholar
• Bond JR, Barry BW. (1988). Hairless mouse skin is limited as a model for assessing the effects of penetration enhancers in human skin. J Invest Dermatol, 90:810–813.
   PubMed Web of Science ®Google Scholar